HUYA Bioscience International

HUYA Bioscience International

HUYA Bioscience International is a San Diego-based company founded by Mireille Gillings.

All edits

Edits on 14 October, 2019
Carla Faraguna
Carla Faraguna edited on 14 October, 2019 9:24 pm
Edits made to:
Article (+9/-8 characters)

Article

HUYA Bioscience raised $48 million in debt financing in April 2015. Investors were not announceannounced. The total amount raised was offered in convertible promissory notes.

Carla Faraguna
Carla Faraguna edited on 14 October, 2019 9:23 pm
Edits made to:
Description (+88/-86 characters)
Topic thumbnail

HUYA Bioscience International

A company identifying and globalizing China's innovations in the pharmaceuticals field

HUYA Bioscience International is a San Diego-based company founded by Mireille Gillings.

Edits on 11 October, 2019
Aleksander Holm
Aleksander Holm approved a suggestion from Golden's AI on 11 October, 2019 6:48 pm
Edits made to:
Article (+5/-5 characters)

Article

Founded in 2004, HUYA Bioscience International is a bio-science and biopharmaceutical company which works to identify and license pre-clinical and clinical-stage compounds coming out of ChinaChina to leverage and extend research efforts and provide a bridge into international development. Through their model, HUYA tries to accelerate development while lowering business risk in introducing new compounds.

Aleksander Holm
Aleksander Holm approved a suggestion from Golden's AI on 11 October, 2019 6:48 pm
Edits made to:
Article (+3/-3 characters)

Article

HBI-8000 is an orally taken, epigenetic drug, and a member of the benzamide class of histone deacetylase inhibitors which works to control how tightly DNADNA is wound around a histone protein. HBI-8000 looks to have immunomodulatory effects regulating antitumor activity and repression of genes associated with drug resistance. The product is currently undergoing a Phase II trial in the US to investigate efficacy and safety.

Aleksander Holm
Aleksander Holm edited on 11 October, 2019 6:40 pm
Edits made to:
Infobox (+10/--1 properties)
Description (+22/-20 characters)
Article (+1822 characters)
People (+31 rows) (+62 cells) (+1386 characters)
Categories (+1 topics)
Topic thumbnail

HUYA Bioscience International

A company dentifyingidentifying and globalizing China's inovationsinnovations in the pharmaceuticals field

Article

Founded in 2004, HUYA Bioscience International is a bio-science and biopharmaceutical company which works to identify and license pre-clinical and clinical-stage compounds coming out of China to leverage and extend research efforts and provide a bridge into international development. Through their model, HUYA tries to accelerate development while lowering business risk in introducing new compounds.

Compounds

HBI-8000

HBI-8000 is an orally taken, epigenetic drug, and a member of the benzamide class of histone deacetylase inhibitors which works to control how tightly DNA is wound around a histone protein. HBI-8000 looks to have immunomodulatory effects regulating antitumor activity and repression of genes associated with drug resistance. The product is currently undergoing a Phase II trial in the US to investigate efficacy and safety.

HBI-3000

HBI-3000 is an intravenous infusion administered multi-ion channel blocker treating atrial fibrillation. The compound is currently in Phase 1 testing.

HBI-3802

HBI-3802 is a small molecule with regenerative properties in cardiac muscle cells and possibly used after myocardial infarction, heart attacks, to strengthen and build the cardiac muscle. The compound stimulates cell differentiation into functional cardiomyocytes, replacing and remodeling dead myocardium with new functional tissue.

Funding

Venture Equity

HUYA Bioscience raised $5 million in April 2009. None of the investors were announced.

Debt Equity

In March of 2012, HUYA Bioscience raised $7.6 million in equity and debt financing. Investors were not announced. $3 million of the financing was through convertible promissory notes.

Debt Financing

HUYA Bioscience raised $48 million in debt financing in April 2015. Investors were not announce. The total amount raised was offered in convertible promissory notes.

People

Name
Role
LinkedIn

Chen Yao, MD

Advisor

Christopher Kemmerer, PhD

Vice President, Chemistry, Manufacturing and Controls

Chun-Lin Chen, PhD, EMBA

Advisor

Clement Gingras

Chief Technology Officer and Chief Operating Officer Asia

Curtis Tyree, PhD

Senior Vice President, Strategic Planning

Gloria Lee, MD, PhD

Chief Medical Officer

Guozhong Rui, PhD

Advisor

Hiroshi Onogi, MD

Executive Vice President, Head of Clinical Development - Japan

Jin Li, MD

Advisor

Jonathan O'Connell

Chief Financial Officer

Jun Sun, PhD

Vice President, Business Development - China

Ken Nanami

Director, Clinical Operations

Kenneth D. Polin, Esq.

Chief Administrative Officer and General Counsel

Martin Doorbar

Global Head CMC and Manufacturing Operations

Masutoshi Toya

Clinical Project Management Director

Mireille Gillings, PhD, Hon DSc

CEO and Executive Chair

Qishan Wang, PhD

Director Shanghai Office, East China

Reid Bissonnette, PhD

Vice President, Pharmacology

Robert Goodenow, PhD

President

Rulun Zhou, MD, MS

Senior Director Beijing Office, North China

Shawn Shao-Hui Zhang, PhD

Advisor

Shun Lu, MD, PhD

Advisor

Suzanne Romano, PhD

Vice President, Product Evaluation & Early Stage Development

Xiaoping Ye, DPhil, EMBA

Advisor

Xinhui Luan, PhD

Advisor

Page 1 of 2

Infobox

Company status
Active
Legal name
HUYA Bioscience International LLC
Tagline
The leader in globalizing China's biopharma innovation
Full address
12531 High Bluff Drive, Suite 138, San Diego, CA 92130

Categories

Edits on 9 July, 2019
Golden AI"Crunchbase 2013 Snapshot (C) 2013 https://data.crunchbase.com/docs/2013-snapshot#section-using-the-snapshot"
Golden AI edited on 9 July, 2019 2:49 pm
Edits made to:
Infobox (+1 properties)
Edits on 7 March, 2019
Golden AI
Golden AI edited on 7 March, 2019 10:05 pm
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 1 September, 2018
Golden AI"Update description"
Golden AI edited on 1 September, 2018 12:34 am
Edits made to:
Description (+84/-21 characters)
Topic thumbnail

HUYA Bioscience International

Biotechnology company

A company dentifying and globalizing China's inovations in the pharmaceuticals field

Edits on 19 July, 2018
Golden AI"Update locations in infobox"
Golden AI edited on 19 July, 2018 8:50 pm

Infobox

Location
Edits on 29 June, 2018
Golden AI"Update infobox"
Golden AI edited on 29 June, 2018 5:40 pm

Infobox

Edits on 29 May, 2018
Golden AI"Initial topic creation"
Golden AI created this topic on 29 May, 2018 9:37 pm
Edits made to:
Description (+21 characters)
Categories (+1 topics)
Topic thumbnail

 HUYA Bioscience International

Biotechnology company

Categories

No more activity to show.

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.